
Featured market report: Summary of dry eye syndrome
pharmafile | November 5, 2015 | Feature | |Â Â dry eye disease, dry eye syndrome, lifitegrastÂ
This report provides the current prevalent population for dry eye syndrome across seven major markets.
It includes data for the USA, France, Germany, Italy, Spain, UK and Japan, split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of dry eye syndrome. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Dry Eye Syndrome have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
For more information and to purchase the report, click here.
Related Content

Nordic Pharma’s Lacrifill canalicular gel gains CE mark approval and set for European launch
International pharma company Nordic Pharma has announced that its Lacrifill treatment for dry eye disease …

All eyes on dry eye disease
Dr Matthew Fyfe, Head of Chemistry and Intellectual Property at TopiVert, gives an illuminating look …

FDA to decide on Shire blockbuster hopeful
The FDA has accepted Shire’s new drug application (NDA) for its dry eye disease drug …






